Read story on San Francisco Public Press
Summary
Hepatitis B, often called a “silent killer,” disproportionately affects Asian Americans and Pacific Islanders, yet remains underrecognized and undertreated. Many infected individuals show no symptoms until irreversible liver damage or cancer develops. Only about 13% of people with chronic hepatitis B in the U.S. even know they have it.
The Trump administration’s slashing of medical research funding threaten progress toward a cure for hepatitis B. The budget calls for $1.8 billion in cuts to the National Institutes of Health and the elimination of all federal funding for the National Institute on Minority Health and Health Disparities, along with additional cuts to the Food and Drug Administration, which has final say on approving new drugs and treatments.
